Organon Misses Q1 2026 Revenue Estimates
Pharmaceutical company Organon (NYSE:OGN) reported Q1 2026 results with revenue of $1.46 billion, down 3.5% year-over-year, and non-GAAP earnings per share of $0.71, missing consensus estimates by 16.8%.
Key Numbers
Pharmaceutical company Organon (NYSE:OGN) reported its first quarter 2026 financial results, with revenue of $1.46 billion, a 3.5% decline compared to the same period last year. Non-GAAP earnings per share came in at $0.71, missing analyst consensus estimates by 16.8%.
Key Financial Results
| Metric | Value | YoY Change |
|---|---|---|
| Revenue | $1.46 billion | -3.5% |
| Non-GAAP EPS | $0.71 | -16.8% vs. estimates |
Highlights from the Report
The company attributed the revenue decline to lower demand for certain key products and competitive pressures in specific markets. No further details were provided on the reasons for the decline.
Future Guidance
Organon did not provide formal guidance for the next quarter or fiscal year 2026, leaving investors uncertain about future performance.
Impact on the Stock
Organon's stock (OGN) is expected to face selling pressure following the disappointing results, with both revenue and earnings falling short of expectations. Analysts may revise their estimates downward.
What This Means for Investors
Organon's weak Q1 results are a negative signal for investors, especially given the lack of clear guidance. Investors should monitor any updates from the company regarding strategies to offset the decline.
Frequently Asked Questions
Found this useful? Share it